Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs
Abstract Studies have shown the beneficial effects of Therapeutic Drug Monitoring (TDM) for some antidepressant (tricyclic antidepressants) and antipsychotic drugs (e.g. haloperidol or clozapine). For these drugs, TDM should be used as standard care. Moreover, TDM is useful for a number of specific...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Hiemke, Christoph [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Walter de Gruyter ; 2005 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Walter de Gruyter |
|---|---|
| Umfang: |
8 |
| Reproduktion: |
Walter de Gruyter Online Zeitschriften |
|---|---|
| Übergeordnetes Werk: |
In: 28(2005), 4 vom: 01. Juni, Seite 326-333 volume:28 ; year:2005 ; number:4 ; day:01 ; month:06 ; pages:326-333 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1515/LabMed.2004.049 |
|---|
| Katalog-ID: |
NLEJ247331023 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ247331023 | ||
| 003 | DE-627 | ||
| 005 | 20230506082248.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220814s2005 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1515/LabMed.2004.049 |2 doi | |
| 028 | 5 | 2 | |a artikel_Grundlieferung.pp |
| 035 | |a (DE-627)NLEJ247331023 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Hiemke, Christoph |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs |
| 264 | 1 | |b Walter de Gruyter |c 2005 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Walter de Gruyter | ||
| 520 | |a Abstract Studies have shown the beneficial effects of Therapeutic Drug Monitoring (TDM) for some antidepressant (tricyclic antidepressants) and antipsychotic drugs (e.g. haloperidol or clozapine). For these drugs, TDM should be used as standard care. Moreover, TDM is useful for a number of specific indications such as control of compliance, drug-drug interactions, comorbidity, nonresponse, or unexpected side effects. In practice, blood should be taken under steady state conditions and analytical methods should be sufficiently sensitive (lower limit of quantification about 5 to 50 ng/ml) and precise (day-to-day variabilities below 20%). Chromatographic methods are suitable, whereas immunoassays for antidepressants and radioreceptor assays for antipsychotics have insufficient reliability. TDM results should be reported with inclusion of a qualified comment as soon as possible after blood withdrawal. The clinical decision must consider not only blood levels but also time under drug therapy, clinical improvement and side effects. Some studies have shown an economical impact of TDM. The potential beneficial effects of TDM in anti-psychotic and anti-depressive drug therapy are not adequately utilized, since psychiatrists order these tests too rarely. | ||
| 533 | |f Walter de Gruyter Online Zeitschriften | ||
| 650 | 4 | |a Antidepressiva | |
| 650 | 4 | |a Antipsychotika | |
| 650 | 4 | |a Neuroleptika | |
| 650 | 4 | |a Therapeutisches Drug Monitoring | |
| 650 | 4 | |a Therapieoptimierung | |
| 650 | 4 | |a antidepressants | |
| 650 | 4 | |a antipsychotics | |
| 650 | 4 | |a neuroleptics | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a therapeutic drug monitoring | |
| 773 | 0 | 8 | |i In |g 28(2005), 4 vom: 01. Juni, Seite 326-333 |
| 773 | 1 | 8 | |g volume:28 |g year:2005 |g number:4 |g day:01 |g month:06 |g pages:326-333 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1515/LabMed.2004.049 |z Deutschlandweit zugänglich |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DGR | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2005 |e 4 |b 01 |c 06 |h 326-333 |g 8 | ||
| author_variant |
c h ch |
|---|---|
| matchkey_str |
hiemkechristoph:2005----:hrpuicedumntrnvnniersianatpyhtkteaetcoioigfni |
| hierarchy_sort_str |
2005 |
| publishDate |
2005 |
| allfields |
10.1515/LabMed.2004.049 doi artikel_Grundlieferung.pp (DE-627)NLEJ247331023 DE-627 ger DE-627 rakwb Hiemke, Christoph verfasserin aut Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs Walter de Gruyter 2005 8 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Walter de Gruyter Abstract Studies have shown the beneficial effects of Therapeutic Drug Monitoring (TDM) for some antidepressant (tricyclic antidepressants) and antipsychotic drugs (e.g. haloperidol or clozapine). For these drugs, TDM should be used as standard care. Moreover, TDM is useful for a number of specific indications such as control of compliance, drug-drug interactions, comorbidity, nonresponse, or unexpected side effects. In practice, blood should be taken under steady state conditions and analytical methods should be sufficiently sensitive (lower limit of quantification about 5 to 50 ng/ml) and precise (day-to-day variabilities below 20%). Chromatographic methods are suitable, whereas immunoassays for antidepressants and radioreceptor assays for antipsychotics have insufficient reliability. TDM results should be reported with inclusion of a qualified comment as soon as possible after blood withdrawal. The clinical decision must consider not only blood levels but also time under drug therapy, clinical improvement and side effects. Some studies have shown an economical impact of TDM. The potential beneficial effects of TDM in anti-psychotic and anti-depressive drug therapy are not adequately utilized, since psychiatrists order these tests too rarely. Walter de Gruyter Online Zeitschriften Antidepressiva Antipsychotika Neuroleptika Therapeutisches Drug Monitoring Therapieoptimierung antidepressants antipsychotics neuroleptics pharmacokinetics therapeutic drug monitoring In 28(2005), 4 vom: 01. Juni, Seite 326-333 volume:28 year:2005 number:4 day:01 month:06 pages:326-333 extent:8 https://doi.org/10.1515/LabMed.2004.049 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 28 2005 4 01 06 326-333 8 |
| spelling |
10.1515/LabMed.2004.049 doi artikel_Grundlieferung.pp (DE-627)NLEJ247331023 DE-627 ger DE-627 rakwb Hiemke, Christoph verfasserin aut Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs Walter de Gruyter 2005 8 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Walter de Gruyter Abstract Studies have shown the beneficial effects of Therapeutic Drug Monitoring (TDM) for some antidepressant (tricyclic antidepressants) and antipsychotic drugs (e.g. haloperidol or clozapine). For these drugs, TDM should be used as standard care. Moreover, TDM is useful for a number of specific indications such as control of compliance, drug-drug interactions, comorbidity, nonresponse, or unexpected side effects. In practice, blood should be taken under steady state conditions and analytical methods should be sufficiently sensitive (lower limit of quantification about 5 to 50 ng/ml) and precise (day-to-day variabilities below 20%). Chromatographic methods are suitable, whereas immunoassays for antidepressants and radioreceptor assays for antipsychotics have insufficient reliability. TDM results should be reported with inclusion of a qualified comment as soon as possible after blood withdrawal. The clinical decision must consider not only blood levels but also time under drug therapy, clinical improvement and side effects. Some studies have shown an economical impact of TDM. The potential beneficial effects of TDM in anti-psychotic and anti-depressive drug therapy are not adequately utilized, since psychiatrists order these tests too rarely. Walter de Gruyter Online Zeitschriften Antidepressiva Antipsychotika Neuroleptika Therapeutisches Drug Monitoring Therapieoptimierung antidepressants antipsychotics neuroleptics pharmacokinetics therapeutic drug monitoring In 28(2005), 4 vom: 01. Juni, Seite 326-333 volume:28 year:2005 number:4 day:01 month:06 pages:326-333 extent:8 https://doi.org/10.1515/LabMed.2004.049 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 28 2005 4 01 06 326-333 8 |
| allfields_unstemmed |
10.1515/LabMed.2004.049 doi artikel_Grundlieferung.pp (DE-627)NLEJ247331023 DE-627 ger DE-627 rakwb Hiemke, Christoph verfasserin aut Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs Walter de Gruyter 2005 8 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Walter de Gruyter Abstract Studies have shown the beneficial effects of Therapeutic Drug Monitoring (TDM) for some antidepressant (tricyclic antidepressants) and antipsychotic drugs (e.g. haloperidol or clozapine). For these drugs, TDM should be used as standard care. Moreover, TDM is useful for a number of specific indications such as control of compliance, drug-drug interactions, comorbidity, nonresponse, or unexpected side effects. In practice, blood should be taken under steady state conditions and analytical methods should be sufficiently sensitive (lower limit of quantification about 5 to 50 ng/ml) and precise (day-to-day variabilities below 20%). Chromatographic methods are suitable, whereas immunoassays for antidepressants and radioreceptor assays for antipsychotics have insufficient reliability. TDM results should be reported with inclusion of a qualified comment as soon as possible after blood withdrawal. The clinical decision must consider not only blood levels but also time under drug therapy, clinical improvement and side effects. Some studies have shown an economical impact of TDM. The potential beneficial effects of TDM in anti-psychotic and anti-depressive drug therapy are not adequately utilized, since psychiatrists order these tests too rarely. Walter de Gruyter Online Zeitschriften Antidepressiva Antipsychotika Neuroleptika Therapeutisches Drug Monitoring Therapieoptimierung antidepressants antipsychotics neuroleptics pharmacokinetics therapeutic drug monitoring In 28(2005), 4 vom: 01. Juni, Seite 326-333 volume:28 year:2005 number:4 day:01 month:06 pages:326-333 extent:8 https://doi.org/10.1515/LabMed.2004.049 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 28 2005 4 01 06 326-333 8 |
| allfieldsGer |
10.1515/LabMed.2004.049 doi artikel_Grundlieferung.pp (DE-627)NLEJ247331023 DE-627 ger DE-627 rakwb Hiemke, Christoph verfasserin aut Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs Walter de Gruyter 2005 8 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Walter de Gruyter Abstract Studies have shown the beneficial effects of Therapeutic Drug Monitoring (TDM) for some antidepressant (tricyclic antidepressants) and antipsychotic drugs (e.g. haloperidol or clozapine). For these drugs, TDM should be used as standard care. Moreover, TDM is useful for a number of specific indications such as control of compliance, drug-drug interactions, comorbidity, nonresponse, or unexpected side effects. In practice, blood should be taken under steady state conditions and analytical methods should be sufficiently sensitive (lower limit of quantification about 5 to 50 ng/ml) and precise (day-to-day variabilities below 20%). Chromatographic methods are suitable, whereas immunoassays for antidepressants and radioreceptor assays for antipsychotics have insufficient reliability. TDM results should be reported with inclusion of a qualified comment as soon as possible after blood withdrawal. The clinical decision must consider not only blood levels but also time under drug therapy, clinical improvement and side effects. Some studies have shown an economical impact of TDM. The potential beneficial effects of TDM in anti-psychotic and anti-depressive drug therapy are not adequately utilized, since psychiatrists order these tests too rarely. Walter de Gruyter Online Zeitschriften Antidepressiva Antipsychotika Neuroleptika Therapeutisches Drug Monitoring Therapieoptimierung antidepressants antipsychotics neuroleptics pharmacokinetics therapeutic drug monitoring In 28(2005), 4 vom: 01. Juni, Seite 326-333 volume:28 year:2005 number:4 day:01 month:06 pages:326-333 extent:8 https://doi.org/10.1515/LabMed.2004.049 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 28 2005 4 01 06 326-333 8 |
| allfieldsSound |
10.1515/LabMed.2004.049 doi artikel_Grundlieferung.pp (DE-627)NLEJ247331023 DE-627 ger DE-627 rakwb Hiemke, Christoph verfasserin aut Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs Walter de Gruyter 2005 8 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Walter de Gruyter Abstract Studies have shown the beneficial effects of Therapeutic Drug Monitoring (TDM) for some antidepressant (tricyclic antidepressants) and antipsychotic drugs (e.g. haloperidol or clozapine). For these drugs, TDM should be used as standard care. Moreover, TDM is useful for a number of specific indications such as control of compliance, drug-drug interactions, comorbidity, nonresponse, or unexpected side effects. In practice, blood should be taken under steady state conditions and analytical methods should be sufficiently sensitive (lower limit of quantification about 5 to 50 ng/ml) and precise (day-to-day variabilities below 20%). Chromatographic methods are suitable, whereas immunoassays for antidepressants and radioreceptor assays for antipsychotics have insufficient reliability. TDM results should be reported with inclusion of a qualified comment as soon as possible after blood withdrawal. The clinical decision must consider not only blood levels but also time under drug therapy, clinical improvement and side effects. Some studies have shown an economical impact of TDM. The potential beneficial effects of TDM in anti-psychotic and anti-depressive drug therapy are not adequately utilized, since psychiatrists order these tests too rarely. Walter de Gruyter Online Zeitschriften Antidepressiva Antipsychotika Neuroleptika Therapeutisches Drug Monitoring Therapieoptimierung antidepressants antipsychotics neuroleptics pharmacokinetics therapeutic drug monitoring In 28(2005), 4 vom: 01. Juni, Seite 326-333 volume:28 year:2005 number:4 day:01 month:06 pages:326-333 extent:8 https://doi.org/10.1515/LabMed.2004.049 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 28 2005 4 01 06 326-333 8 |
| source |
In 28(2005), 4 vom: 01. Juni, Seite 326-333 volume:28 year:2005 number:4 day:01 month:06 pages:326-333 extent:8 |
| sourceStr |
In 28(2005), 4 vom: 01. Juni, Seite 326-333 volume:28 year:2005 number:4 day:01 month:06 pages:326-333 extent:8 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Antidepressiva Antipsychotika Neuroleptika Therapeutisches Drug Monitoring Therapieoptimierung antidepressants antipsychotics neuroleptics pharmacokinetics therapeutic drug monitoring |
| isfreeaccess_bool |
false |
| authorswithroles_txt_mv |
Hiemke, Christoph @@aut@@ |
| publishDateDaySort_date |
2005-06-01T00:00:00Z |
| id |
NLEJ247331023 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ247331023</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506082248.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220814s2005 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/LabMed.2004.049</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">artikel_Grundlieferung.pp</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ247331023</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hiemke, Christoph</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="b">Walter de Gruyter</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Walter de Gruyter</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Studies have shown the beneficial effects of Therapeutic Drug Monitoring (TDM) for some antidepressant (tricyclic antidepressants) and antipsychotic drugs (e.g. haloperidol or clozapine). For these drugs, TDM should be used as standard care. Moreover, TDM is useful for a number of specific indications such as control of compliance, drug-drug interactions, comorbidity, nonresponse, or unexpected side effects. In practice, blood should be taken under steady state conditions and analytical methods should be sufficiently sensitive (lower limit of quantification about 5 to 50 ng/ml) and precise (day-to-day variabilities below 20%). Chromatographic methods are suitable, whereas immunoassays for antidepressants and radioreceptor assays for antipsychotics have insufficient reliability. TDM results should be reported with inclusion of a qualified comment as soon as possible after blood withdrawal. The clinical decision must consider not only blood levels but also time under drug therapy, clinical improvement and side effects. Some studies have shown an economical impact of TDM. The potential beneficial effects of TDM in anti-psychotic and anti-depressive drug therapy are not adequately utilized, since psychiatrists order these tests too rarely.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Walter de Gruyter Online Zeitschriften</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antidepressiva</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antipsychotika</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuroleptika</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Therapeutisches Drug Monitoring</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Therapieoptimierung</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antidepressants</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antipsychotics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">neuroleptics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pharmacokinetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">therapeutic drug monitoring</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="g">28(2005), 4 vom: 01. Juni, Seite 326-333</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:28</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:4</subfield><subfield code="g">day:01</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:326-333</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/LabMed.2004.049</subfield><subfield code="z">Deutschlandweit zugänglich</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DGR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">28</subfield><subfield code="j">2005</subfield><subfield code="e">4</subfield><subfield code="b">01</subfield><subfield code="c">06</subfield><subfield code="h">326-333</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
| series2 |
Walter de Gruyter Online Zeitschriften |
| author |
Hiemke, Christoph |
| spellingShingle |
Hiemke, Christoph misc Antidepressiva misc Antipsychotika misc Neuroleptika misc Therapeutisches Drug Monitoring misc Therapieoptimierung misc antidepressants misc antipsychotics misc neuroleptics misc pharmacokinetics misc therapeutic drug monitoring Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs |
| authorStr |
Hiemke, Christoph |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs Antidepressiva Antipsychotika Neuroleptika Therapeutisches Drug Monitoring Therapieoptimierung antidepressants antipsychotics neuroleptics pharmacokinetics therapeutic drug monitoring |
| publisher |
Walter de Gruyter |
| publisherStr |
Walter de Gruyter |
| topic |
misc Antidepressiva misc Antipsychotika misc Neuroleptika misc Therapeutisches Drug Monitoring misc Therapieoptimierung misc antidepressants misc antipsychotics misc neuroleptics misc pharmacokinetics misc therapeutic drug monitoring |
| topic_unstemmed |
misc Antidepressiva misc Antipsychotika misc Neuroleptika misc Therapeutisches Drug Monitoring misc Therapieoptimierung misc antidepressants misc antipsychotics misc neuroleptics misc pharmacokinetics misc therapeutic drug monitoring |
| topic_browse |
misc Antidepressiva misc Antipsychotika misc Neuroleptika misc Therapeutisches Drug Monitoring misc Therapieoptimierung misc antidepressants misc antipsychotics misc neuroleptics misc pharmacokinetics misc therapeutic drug monitoring |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| isfreeaccess_txt |
false |
| title |
Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs |
| ctrlnum |
(DE-627)NLEJ247331023 |
| title_full |
Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs |
| author_sort |
Hiemke, Christoph |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2005 |
| contenttype_str_mv |
txt |
| container_start_page |
326 |
| author_browse |
Hiemke, Christoph |
| container_volume |
28 |
| physical |
8 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Hiemke, Christoph |
| doi_str_mv |
10.1515/LabMed.2004.049 |
| title_sort |
therapeutisches drug monitoring von antidepressiva und antipsychotika/therapeutic monitoring of antidepressant and antipsychotic drugs |
| title_auth |
Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs |
| abstract |
Abstract Studies have shown the beneficial effects of Therapeutic Drug Monitoring (TDM) for some antidepressant (tricyclic antidepressants) and antipsychotic drugs (e.g. haloperidol or clozapine). For these drugs, TDM should be used as standard care. Moreover, TDM is useful for a number of specific indications such as control of compliance, drug-drug interactions, comorbidity, nonresponse, or unexpected side effects. In practice, blood should be taken under steady state conditions and analytical methods should be sufficiently sensitive (lower limit of quantification about 5 to 50 ng/ml) and precise (day-to-day variabilities below 20%). Chromatographic methods are suitable, whereas immunoassays for antidepressants and radioreceptor assays for antipsychotics have insufficient reliability. TDM results should be reported with inclusion of a qualified comment as soon as possible after blood withdrawal. The clinical decision must consider not only blood levels but also time under drug therapy, clinical improvement and side effects. Some studies have shown an economical impact of TDM. The potential beneficial effects of TDM in anti-psychotic and anti-depressive drug therapy are not adequately utilized, since psychiatrists order these tests too rarely. © Walter de Gruyter |
| abstractGer |
Abstract Studies have shown the beneficial effects of Therapeutic Drug Monitoring (TDM) for some antidepressant (tricyclic antidepressants) and antipsychotic drugs (e.g. haloperidol or clozapine). For these drugs, TDM should be used as standard care. Moreover, TDM is useful for a number of specific indications such as control of compliance, drug-drug interactions, comorbidity, nonresponse, or unexpected side effects. In practice, blood should be taken under steady state conditions and analytical methods should be sufficiently sensitive (lower limit of quantification about 5 to 50 ng/ml) and precise (day-to-day variabilities below 20%). Chromatographic methods are suitable, whereas immunoassays for antidepressants and radioreceptor assays for antipsychotics have insufficient reliability. TDM results should be reported with inclusion of a qualified comment as soon as possible after blood withdrawal. The clinical decision must consider not only blood levels but also time under drug therapy, clinical improvement and side effects. Some studies have shown an economical impact of TDM. The potential beneficial effects of TDM in anti-psychotic and anti-depressive drug therapy are not adequately utilized, since psychiatrists order these tests too rarely. © Walter de Gruyter |
| abstract_unstemmed |
Abstract Studies have shown the beneficial effects of Therapeutic Drug Monitoring (TDM) for some antidepressant (tricyclic antidepressants) and antipsychotic drugs (e.g. haloperidol or clozapine). For these drugs, TDM should be used as standard care. Moreover, TDM is useful for a number of specific indications such as control of compliance, drug-drug interactions, comorbidity, nonresponse, or unexpected side effects. In practice, blood should be taken under steady state conditions and analytical methods should be sufficiently sensitive (lower limit of quantification about 5 to 50 ng/ml) and precise (day-to-day variabilities below 20%). Chromatographic methods are suitable, whereas immunoassays for antidepressants and radioreceptor assays for antipsychotics have insufficient reliability. TDM results should be reported with inclusion of a qualified comment as soon as possible after blood withdrawal. The clinical decision must consider not only blood levels but also time under drug therapy, clinical improvement and side effects. Some studies have shown an economical impact of TDM. The potential beneficial effects of TDM in anti-psychotic and anti-depressive drug therapy are not adequately utilized, since psychiatrists order these tests too rarely. © Walter de Gruyter |
| collection_details |
GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE |
| container_issue |
4 |
| title_short |
Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs |
| url |
https://doi.org/10.1515/LabMed.2004.049 |
| remote_bool |
true |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1515/LabMed.2004.049 |
| up_date |
2024-07-06T10:22:24.445Z |
| _version_ |
1803824759513808896 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ247331023</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506082248.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220814s2005 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/LabMed.2004.049</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">artikel_Grundlieferung.pp</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ247331023</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hiemke, Christoph</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="b">Walter de Gruyter</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Walter de Gruyter</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Studies have shown the beneficial effects of Therapeutic Drug Monitoring (TDM) for some antidepressant (tricyclic antidepressants) and antipsychotic drugs (e.g. haloperidol or clozapine). For these drugs, TDM should be used as standard care. Moreover, TDM is useful for a number of specific indications such as control of compliance, drug-drug interactions, comorbidity, nonresponse, or unexpected side effects. In practice, blood should be taken under steady state conditions and analytical methods should be sufficiently sensitive (lower limit of quantification about 5 to 50 ng/ml) and precise (day-to-day variabilities below 20%). Chromatographic methods are suitable, whereas immunoassays for antidepressants and radioreceptor assays for antipsychotics have insufficient reliability. TDM results should be reported with inclusion of a qualified comment as soon as possible after blood withdrawal. The clinical decision must consider not only blood levels but also time under drug therapy, clinical improvement and side effects. Some studies have shown an economical impact of TDM. The potential beneficial effects of TDM in anti-psychotic and anti-depressive drug therapy are not adequately utilized, since psychiatrists order these tests too rarely.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Walter de Gruyter Online Zeitschriften</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antidepressiva</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antipsychotika</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuroleptika</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Therapeutisches Drug Monitoring</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Therapieoptimierung</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antidepressants</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antipsychotics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">neuroleptics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pharmacokinetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">therapeutic drug monitoring</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="g">28(2005), 4 vom: 01. Juni, Seite 326-333</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:28</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:4</subfield><subfield code="g">day:01</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:326-333</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/LabMed.2004.049</subfield><subfield code="z">Deutschlandweit zugänglich</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DGR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">28</subfield><subfield code="j">2005</subfield><subfield code="e">4</subfield><subfield code="b">01</subfield><subfield code="c">06</subfield><subfield code="h">326-333</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
| score |
7.4000187 |